It's more than just producing and giving drugs to these needy countries, there needs to be a check and balance system to ensure work is being done as prescribed (Hodgett et al., 2005).
A motivational factor is that these pharmaceutical corporations had a solid return on investment on research and development, thus there was a motivational flag for further research. Some new ones work better than those available some years ago. If the drugs were sold at present prices as of now, there wouldn't be research and development funds, driving the new projects into the ground (state gov). Also, if there isn't any point in producing and manufacturing such drugs as these third world countries can't afford them, the industrialized countries for that matter are adversely affected by AIDS syndrome too. It's a widespread disease. With the passage of time, the AIDS drugs will be cheaply available, when expenses will be met on the research and development front. People do forget that pharmaceutical companies are still a business enterprise which means profits must be returned for its viability. Pharmaceuticals aren't an exception to the rule. They can't afford to let their products get duplicated and mass market by some lesser company. All these factors must be taken in account (Westerhaus and Castro, 2006).
The lack of medical infrastructure in the third world is appalling. This doesn't have any relation to cost of medicine distribution, but distribution becomes intricate due to lack of a medical infrastructure (Bate and Tren, 2004). There are many ifs and buts to be addressed first. Drugs are different unlike food and water distributed by volunteers. Medical labs come into play, medical help is needed, testing drugs and posting results and an unlimited supply of drugs as it's a daily requirement (Taylor, 2004). Put all of this into context and the picture becomes only complex. It adds costs at the same time.
Insinuation of prevention
People tend to neglect the role of advertising. AIDS is a disease which has no cure, thus preventive advertising must be aired. These drugs are imperative for the AIDS population. The third world countries should focus on campaigning against AIDS and creating awareness. The virus is lightning fast and it can turn tables for many countries. The first step in curbing AIDS is to prevent it. Prevention is better than cure. The rate at which they AIDS is spreading must be cut down. The numbers should be lessened. This means preventive campaign must play a pivotal role in this regard. There is no cure for AIDS, not in the immediate future (Avert.org (a)).
In the end
The patented drugs have an intellectual property rights stamped on them, the aim is to distribute the AID drugs to the third world countries. It does have its ins and outs. Countries aren't strong enough to have a concrete pharmaceutical industry; there are huge mounting debts to be paid off as well as people can't afford the basic necessities of life. Such poverty stricken countries can't solve their pharmaceutical issues themselves while coping with bigger issues at hand. The global community should be able to develop a noteworthy network and fuel the infected population with adequate drugs needed to curb down disease. The case analysis clearly shows that it's not an easy task at hand. There are many interests and legal issues abound to go through the process first. Discussions and meetings have had a nice influence on raising awareness and finding a compromise. An ultimate solution which caters to each interest is not possible. Due to this, the population affected by AIDS is the most affected by this. Therefore, a commitment is needed from those who have adequate supply of pharmaceuticals and resources at their disposal which will curb down AIDS soon enough (Hodgett et all, 2005).
An imminent danger persists from HIV which could create deeper problems for the AIDS afflicted population. HIV can become resistant to their life prolonging drugs. A whole new generation of drugs would be needed, which will put the world together facing health issues for the last 25 years. In that case, the legal issues will take a backseat as the medical issues will be attended.
Avert.org (a). Accessed online from: http://www.avert.org/prevent-hiv.htm
Avert.org (b). Accessed online from: http://www.avert.org/generic.htm
Avert.org. Accessed online from: http://www.avert.org/aidstarget.htm
Bate, R. And Tren, R. (2004). The Real Obstacles to Sound Treatment of AIDS in Poor Countries. Accessed online from: http://www.fightingmalaria.org/pdfs/treatment_obstacles.pdf
Hodgett, R.M., Luthans, F. And Doh, J. (2005). International Management, 6th Ed. McGraw Hill.
State.gov. Accessed online from: http://usinfo.state.gov/products/pubs/intelprp/industry.htm
Taylor, Y. (2004). Battling HIV / AIDS: A Decision Maker's Guide to the Procurement of Medicines and Related Supplies. Accessed online from: http://siteresources.worldbank.org/INTPROCUREMENT/Resources/Technical-Guide-Procure-HIV-AIDS-Meds.pdf
Westerhaus, M. And Castro, A. (2006) How Do Intellectual Property Law and International Trade Agreements Affect Access to Antiretroviral Therapy? PLoS Med 3(8): e332. Accessed online from: http://medicine.plosjournals.org/perlserv?request=get-document&doi=10.1371/journal.pmed.0030332